Skip to main content

Table 1 Baseline characteristics of study population according to treatment group

From: Efficacy of zoledronic acid for chronic low back pain associated with Modic changes in magnetic resonance imaging

Characteristics

Zoledronic acid

Placebo

 

n = 20

n = 20

Sex, n (%) men

15 (75)

11 (55)

Age, mean (SD) years

49 (9.3)

51 (7.3)

Smoking, n (%) regular smokers*

5 (25)

6 (30)

BMI, mean (SD) kg/m

26 (3.3)

27 (3.2)

Workload, n (%)

  

   -Sedentary work with limited walking

4 (20)

4 (22)

   -Fairly light work with considerable walking but no lifting or carrying heavy objects

4 (20)

3 (17)

   -Fairly strenuous work with walking and lifting heavy objects or climbing stairs or uphil

8 (40)

6 (33)

   -Very strenuous work with lifting or carrying heavy objects such as shovelling, digging or hammering

4 (20)

5 (28)

Type of worst MC-lesion**, n

  

   Type I

1

1

   Type I/II

19

18

   Type II

0

1

MC at two or more levels, n (%)

7 (35)

4 (20)

Levels of MC, n

  

   L2/3

4

0

   L3/4

3

5

   L4/5

6

5

   L5/S1

7

10

Duration of LBP, median (IQ range) days

330 (200, 365)

315 (270, 365)

Intensity of LBP, mean (SD)***

6.6 (1.4)

6.8 (1.6)

Duration of leg pain, median (IQ range) days

50 (0, 100)

36 (0, 160)

Intensity of leg pain, mean (SD)***

3.0 (3.1)

2.9 (2.3)

Oswestry Disability Index, %, Mean (SD)

30 (11)

35 (10)

Duration of sick leave during the past year, median (IQ range) days

14 (0, 48)

18 (1, 181)

RAND-36, mean (SD)

50 (8)

50 (7)

RAND-36 physical component, mean (SD)

51 (8)

49 (8)

RAND-36 mental component, mean (SD)

51 (8)

49 (9)

  1. BMI = Body Mass Index, MC = Modic change, LBP = low back pain, SD = standard deviation, IQ = inter-quartile.
  2. *Smoking at least one cigarette/day.
  3. **If different types of MC at two or more levels, classification is based on the assumed severity of the type, i.e. Type I > mixed Type I/II > Type II.
  4. ***Assessed using a 10-cm Visual Analogue Scale (VAS).